**Question:** Ibalizumab was approved by FDA in 2018 April for (REPEAT)

**Core Concept:** Ibalizumab is a human monoclonal antibody used for the treatment of HIV infection, specifically targeting CD4+ T cells. It works by binding to the CD4 receptor, preventing HIV from entering the cell and replicating within it.

**Why the Correct Answer is Right:** Ibalizumab was approved by the FDA in April 2018 for the treatment of multi-drug resistant HIV infection (MDR-HIV), which is a severe form of HIV when standard anti-retroviral therapy fails to control viral replication effectively. Ibalizumab works by targeting CD4+ T cells, which are essential for HIV replication, and preventing the virus from entering these cells. Since the drug directly targets the virus and its host cell, it is effective against MDR-HIV, where the virus has developed resistance to multiple anti-retroviral drugs.

**Why Each Wrong Option is Incorrect:**

A. Ibalizumab is not approved for treating HIV infection, but rather for MDR-HIV (multi-drug resistant HIV). Since standard anti-retroviral therapy can effectively control HIV replication, this option is incorrect.

B. Ibalizumab was not approved in April 2018. The correct answer is D (Ibalizumab was approved in March 2018). This option is incorrect due to the inaccurate timing of the drug approval.

C. While Ibalizumab is effective against MDR-HIV, it is not approved for treating primary HIV infection or early stages of HIV disease. This option is incorrect as the drug is designed for MDR-HIV, not primary infection.

D. Ibalizumab is approved for treating MDR-HIV, which is a severe form of HIV when standard anti-retroviral therapy fails to control viral replication effectively. This option is correct because it highlights the indication of the drug for MDR-HIV treatment.

**Clinical Pearl:** Ibalizumab's approval demonstrates the importance of tailoring treatment strategies for patients with drug-resistant HIV infections. In such cases, a combination therapy that targets viral and host cell components may offer a valuable treatment option, improving patients' quality of life and survival.

In conclusion, Ibalizumab is an example of a tailored treatment approach for MDR-HIV, where standard anti-retroviral therapy has failed to effectively control viral replication.